Treating the host in Dengue: mediators and pathways of resolution as a new therapeutic paradigm

登革热每年感染世界上最贫穷地区128个国家的约4亿人，但目前尚不存在适当的治疗方法。根据巴西卫生部的数据，巴西在过去10年中发生了重大的登革热疫情，过去4年中每年报告的登革热病例约为100万例。(http://portalsaude.saude.gov.br/index.php/situacao-epidemiologica-dados-dengue).仅在5月份，就有报道称，巴西的几个州正在经历一种新的流行病(http://www.bbc.co.uk/news/world-latin-america-32589268).虽然严重疾病只占所有报告病例的大约2%，但没有具体的治疗方法，目前也不可能确定有可能发展成严重疾病的患者。高发病率和没有特定的治疗方案的结合给已经不堪重负的卫生系统带来了巨大的负担。在这项建议中，我们打算研究内源性介质的影响和作用，这些介质可以缓和过度的炎症，并促进对登革热疾病动态的解决。为了研究表达谱，以及这些保护性介质的水平如何随时间变化，我们将使用尖端分析方案(将在英国进行)。为了研究这些介体与人类疾病的相关性，我们将在实验动物中使用患者样本和新的模型(将在巴西完成)。后者反映了患者的几个发现，并提供了一个关键的体内环境，以支持识别和将新疗法转化为人类。我们的新方法建议研究登革热感染期间的炎症过程，更新颖的是，内源性组织保护途径可能对感染过程产生的影响(这一领域通常被称为“炎症消退”)。因此，通过这个项目，我们寻求资金来研究登革热的新机制和过程，目的有两个：1.利用人类样本和动物模型发现登革热的新机制。提供了概念验证结果，即“推动”内源性分解途径可以为登革热提供一种新的治疗途径。这项工作的总体范围是一个新的概念，即为了对抗与感染相关的过度炎症，我们可以治疗宿主，处理感染性病原体，从而使它们处于控制之下，并有利于它们的处置。

Dengue infects some 400 million people in 128 countries each year in poorest regions of the world, yet proper therapeutic treatment does not exist. According to the Brazilian Ministry of Health, significant dengue epidemics have occurred in the last 10 years in Brazil with around 1 million cases/year reported in the last 4 years (http://portalsaude.saude.gov.br/index.php/situacao-epidemiologica-dados-dengue). Only in May it was reported that several States of Brazil are experiencing a new epidemic (http://www.bbc.co.uk/news/world-latin-america-32589268). Although severe disease accounts for only approximately 2% of all reported cases, no specific treatment is available and it is not possible at present to define patients at risk to develop severe disease. The combination of high incidence and no specific therapeutic options places an enormous burden on already over-stretched health systems.In this proposal we intend to study the impact and roles of endogenous mediators that temper excessive inflammation and promote resolution on the dynamics of Dengue disease. To study profiles of expression, and how the levels of these protective mediators change over time, we will use cutting-edge analytical protocols (to be done in the UK). To study the relevance of these mediators to human disease, we will use patient samples as well as novel models in experimental animals (to be done in Brazil). The latter mirror several findings in patients and provide a crucial in vivo environment to underpin identification and the translation of novel therapies into humans. Our new approach proposes to investigate inflammatory processes during the infection of Dengue and, more novel, the impact that endogenous tissue-protective pathways may have on the course of infection (this area is often referred to as 'resolution of inflammation'). Therefore, with this project we seek funding to study new mechanisms and processes in Dengue with the dual aim:1. Discover novel mechanisms in Dengue using human samples and animal models.2. Provide proof-of-concept results that 'pushing' endogenous pathways of resolution can provide a novel therapeutic avenue for Dengue.The over-arching remit of this work is the novel notion that to combat excessive inflammation associated with infection we could treat the host, to deal with the infectious agents, thus keep them under control and favour their disposal.